Recursion Pharmaceuticals, Inc.RXRXNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank50
3Y CAGR+32.7%
5Y CAGR-1.6%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+32.7%/yr
Annual compound
5Y CAGR
-1.6%/yr
Recent acceleration
Percentile
P50
Within normal range
vs 5Y Ago
0.9x
Contraction
Streak
1 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2025 | 35.25% |
| 2024 | 30.34% |
| 2023 | 54.93% |
| 2022 | 15.10% |
| 2021 | 113.63% |
| 2020 | 38.22% |
| 2019 | 0.00% |